MitraClip™ is the world’s first mitral transcatheter edge-to-edge repair (TEER) therapy -- also referred to as TMVr (transcatheter mitral valve repair) -- that delivers a minimally invasive treatment option for select patients with primary or secondary mitral regurgitation (MR) who would otherwise go untreated.1,2 With more than 18 years of clinical experience and over 150,000 patients treated worldwide, MitraClip™ is a well-established procedure with the highest-reported MR reduction, proven safety and survival, and durable clinical outcomes.3,9
Learn about the clinical performance of the MitraClip™ TEER System.
At Abbott, we continue to innovate with the fourth-generation MitraClip™ device. MitraClip™ G4 features several enhancements that offer physicians more treatment options that can be tailored to a patients' unique mitral valve anatomy.
A total of 4 clip sizes—now including clips with wider grasping area—gives physicians the ability to choose a clip size based on each patient’s mitral valve anatomy.1,4-5
With more options to confirm and optimize leaflet grasping, CGA allows physicians to grasp leaflets simultaneously or independently.1,4
Precision and stability from a delivery system specifically designed for the mitral valve facilitates Left Atrial Pressure (LAP) monitoring.4
Transcatheter edge-to-edge repair (TEER) therapy is recommended by the 2022 AHA/ACC/HFSA7 and the 2020 ACC/AHA Guideline8 for select primary and secondary* MR patients. Determining the severity of MR is an important factor in the management of the condition. The guidelines support aggressive monitoring and early action, with the goal of preventing complications due to left ventricular volume overload.7
*Secondary MR patients despite optimal guideline-directed management and therapy (GDMT).
| Product Code | Description | Piece Count |
|---|---|---|
| MCG40100 | MitraClip G4 System | 1 |
| CDS0706-NT | MitraClip G4 NT Clip Delivery System | 1 |
| CDS0706-NTW | MitraClip G4 NTW Clip Delivery System | 1 |
| CDS0706-XT | MitraClip G4 XT Clip Delivery System | 1 |
| CDS0706-XTW | MitraClip G4 XTW Clip Delivery System | 1 |
| SGC0701 | MitraClip G4 Steerable Guide Catheter | 1 |
| Product Code | Description | Piece Count |
|---|---|---|
| SZR01ST | Stabilizer | 1 |
| LFT01ST | Lift | 1 |
| PLT01ST | Support Plate | 1 |
INDICATIONS FOR USE
CONTRAINDICATIONS
The MitraClip G4 System is contraindicated in patients with the following conditions: Patients who cannot tolerate, including allergy or hypersensitivity to, procedural anticoagulation or post procedural anti-platelet regime; Patients with known hypersensitivity to clip components (nickel / titanium, cobalt, chromium, polyester), or with contrast sensitivity; Active endocarditis of the mitral valve; Rheumatic mitral valve disease; Evidence of intracardiac, inferior vena cava (IVC) or femoral venous thrombus
POTENTIAL COMPLICATIONS AND ADVERSE EVENTS
The following ANTICIPATED EVENTS have been identified as possible complications of the MitraClip G4 procedure: Allergic reactions or hypersensitivity to latex, contrast agent, anaesthesia, device materials (nickel / titanium, cobalt, chromium, polyester), and drug reactions to anticoagulation, or antiplatelet drugs, Vascular access complications which may require transfusion or vessel repair including: wound dehiscence, catheter site reactions, Bleeding (including ecchymosis, oozing, hematoma, hemorrhage, retroperitoneal hemorrhage), Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection, perforation / rupture, vascular occlusion, Emboli (air thrombotic material, implant, device component); Peripheral Nerve Injury; Lymphatic complications; Pericardial complications which may require additional intervention, including: Pericardial effuse on, Cardiac tamponade, Pericarditis; Cardiac complications which may require additional interventions or emergency cardiac surgery, including: Cardiac perforation, Atrial septal defect; Mitral valve complications, which may complicate or prevent later surgical repair, including: Chordal entanglement / rupture, Single Leaflet Device Attachment (SLDA), Thrombosis, Dislodgement of previously implanted devices, Tissue damage, Mitral valve stenosis, Persistent or residual mitral regurgitation, Endocarditis; Cardiac arrhythmias (including conduction disorders, atrial arrhythmias, ventricular arrhythmias); Cardiac ischemic conditions (including myocardial infarction, myocardial ischemia, and unstable / stable angina); Venous thromboembolism (including deep vein thrombosis, pulmonary embolism, post procedure pulmonary embolism); Stroke / Cerebrovascular accident (CVA) and Transient Ischemic Attack (TIA); System organ failure: Cardio-respiratory arrest, Worsening heart failure, Pulmonary congestion, Respiratory dysfunction / failure / atelectasis, Renal insufficiency or failure, Shock (including cardiogenic and anaphylactic); Blood cell disorders (including coagulopathy, hemolysis, and Heparin Induced Thrombocytopenia (HIT)); Hypotension / hypertension; Infection including: Urinary Tract Infection (UTI), Pneumonia, Septicemia; Nausea / vomiting; Chest pain; Dyspnea; Edema; Fever or hyperthermia; Pain; Death; Fluoroscopy, Transesophageal echocardiogram (TEE) and Transthoracic echocardiogram (TTE) -related complications: Skin injury or tissue changes due to exposure to ionizing radiation, Esophageal irritation; Esophageal perforation, Gastrointestinal bleeding
MAT-2100249 v3.0